phesgo
roche registration gmbh - pertuzumab, trastuzumab - bryst neoplasmer - antineoplastiske midler - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
evrysdi
roche registration gmbh - risdiplam - muskelatrofi, spinal - andre midler mod forstyrrelser i muskel-skeletsystemet - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
gavreto
roche registration gmbh - pralsetinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
asulox (disp. til og med 2021) vandopløseligt koncentrat
upl europe ltd. (tidligere: united phosphorus ltd.) - asulam - vandopløseligt koncentrat - 400 g/l asulam
corzal 160 se suspoemulsion
upl europe ltd. (tidligere: united phosphorus ltd.) - phenmedipham - suspoemulsion - 157 g/l phenmedipham
stomp suspensionskoncentrat
basf a/s - pendimethalin - suspensionskoncentrat - 400 g/l pendimethalin
narita emulsionskoncentrat
globachem nv - difenoconazol - emulsionskoncentrat - 250 g/l difenoconazol
moxa emulsionskoncentrat
globachem nv - trinexapac-ethyl, trinexapac - emulsionskoncentrat - 250 g/l trinexapac-ethyl ; (~ 222 g/l trinexapac
glybera
uniqure biopharma b.v. - alipogene tiparvovec - hyperlipoproteinæmi type i - lipid modificerende midler - glybera er indiceret til voksne patienter, der er diagnosticeret med familielipoproteinlipasemangel (lpld) og lider af alvorlige eller multiple pancreatitisangreb på trods af fedtbegrænsninger. diagnosen af lpld skal bekræftes ved genetisk testning. indikationen er begrænset til patienter med påviselige niveauer af lpl-protein.
pregabalin pfizer
upjohn eesv - pregabalin - anxiety disorders; epilepsy - antiepileptika, - neuropatiske painpregabalin pfizer er indiceret til behandling af perifere og centrale neuropatiske smerter hos voksne. epilepsypregabalin pfizer er indiceret som adjuverende behandling til voksne med partielle anfald med eller uden sekundær generalisering. generaliseret angst disorderpregabalin pfizer er indiceret til behandling af generaliseret angst (gad) hos voksne.